Apimeds Pharmaceuticals US, Inc. (APUS) Form 8-K — Apr 22, 2026
Apimeds Pharmaceuticals US, Inc. received a notice from NYSE Regulation stating it is not in compliance with continued listing requirements due to the failure to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. The NYSE American has provided an initial cure period ending October 15, 2026, for the company to file the Form 10-K and regain compliance, though the exchange retains the discretion to initiate suspension and delisting procedures earlier.
Price after filing
Close on the filing date to close N calendar days later (from $1.88). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.